Synaptogenix Inc (SNPX)

[XenaLives]

Anavex's drug is now being allowed on a compassionate or "special access" scheme in Australia, patients' doctors may apply to the TGA for access and all 21 patients from the P2a have already been approved for access to the drug because the 5 year OLE has run its course.

What you are describing is research, not data mining for the purpose of changing a failed trial into a successful one.

By the way, you have totally mischaracterized the results of the Anavex P2a.

To get up to speed:

AVXL Compiled Due Diligence 09/29/19 & more ********

See this link:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151418975

PubChem reference for 2-73
https://pubchem.ncbi.nlm.nih.gov/compound/Anavex-2-73#section=Chemical-Disease-Co-Occurrences-in-Literature
see also this post on pubchem info:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158822687

Biology concepts for Alzheimer’s disease (2/20 update)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158531542

Effect of Peroxynitrite:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158822263


TGA requirements have been discussed for years here.
OLE's may be as valuable as a trial for the purpose of Provisional approval.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158539684

ER–mitochondria signaling in Parkinson’s disease (from mapman's link to article post below)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142355746&txt2find=autophagy
PDF of the article cited:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832754/pdf/41419_2017_Article_79.pdf
From "Compiled: MOA and MEDICAL SCIENCE DISCUSSION 09/29/19" at the following link:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151418911

ALS and gut bacteria linked in “remarkable” new Harvard study (from georjejjl)
https://newatlas.com/science/als-gut-bacteria-microbiome-harvard-study/
https://www.anavex.com/wp-content/uploads/2019/12/CTAD2019_ANAVEX2-73_P84_Microbiota_.pdf

From MS Today and tradeherpete “Sigma-1 receptor agonists as potential protective therapies in multiple sclerosis”:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155546193

Aarsland has been busy:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158700775

Biostockclub holds forth :)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158688526

Basic info on PDD from nidan:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158724733

Air pollution particles in young brains linked to Alzheimer's damage
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158774113

Faster drug approval coming world wide:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158796012

Ransomware attack possible reason for delay in PDD trial data:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158710802
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158748463
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158797284

The key lies in being able to accelerate the rate of failure.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158828376

August 15, 2020 Media report on Rett Syndrome trial in Australia.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158829938

COGNITION IN PARKINSON'S
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158855354

Anavex 2-73 made with the SCF, supercritical fluid, for increased bioavaliability.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158825826

From JF comm. 10/08/20, w/ interesting PD comments and future---something about news in October:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158790564